Shots: The filling is based on the results of P-III IMpassion130 study, assessing Tecentriq + Abraxane vs PBO + Abraxane in 902 patients with 1L unresectable LA/M TNBC in ratio (1:1) P-III IMpassion130 study results: mPFS (7.2 vs 5.5mos.); OS (25.0 vs 15.5mos.); no new safety signals, Presented at ESMO 2018. The expected FDA approval […]Read More
Tags : Abraxane (nab-paclitaxel)
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US